Cargando…

Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis

BACKGROUND: The role of HLA-DR antigens in the clinicopathological features of autoimmune hepatitis (AIH) is not clearly understood. We examined the implications of HLA-DR antigens in Japanese AIH, including the effect of HLA-DR4 on the age and pattern of AIH onset, clinicopathological features, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Furumoto, Yohei, Asano, Toru, Sugita, Tomonori, Abe, Hiroshi, Chuganji, Yoshimichi, Fujiki, Kazuhiko, Sakata, Akihiko, Aizawa, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618735/
https://www.ncbi.nlm.nih.gov/pubmed/26489422
http://dx.doi.org/10.1186/s12876-015-0360-9
_version_ 1782396967737884672
author Furumoto, Yohei
Asano, Toru
Sugita, Tomonori
Abe, Hiroshi
Chuganji, Yoshimichi
Fujiki, Kazuhiko
Sakata, Akihiko
Aizawa, Yoshio
author_facet Furumoto, Yohei
Asano, Toru
Sugita, Tomonori
Abe, Hiroshi
Chuganji, Yoshimichi
Fujiki, Kazuhiko
Sakata, Akihiko
Aizawa, Yoshio
author_sort Furumoto, Yohei
collection PubMed
description BACKGROUND: The role of HLA-DR antigens in the clinicopathological features of autoimmune hepatitis (AIH) is not clearly understood. We examined the implications of HLA-DR antigens in Japanese AIH, including the effect of HLA-DR4 on the age and pattern of AIH onset, clinicopathological features, and treatment efficacy. METHODS: A total of 132 AIH patients consecutively diagnosed and treated in 2000–2014 at 2 major hepatology centers of eastern Tokyo district were the subjects of this study. The frequency of HLA-DR phenotypes was compared with that in the healthy Japanese population. AIH patients were divided into HLA-DR4–positive or HLA-DR4–negative groups and further sub-classified into elderly and young-to-middle-aged groups, and differences in clinical and histological features were examined. Clinical features associated with the response to immunosuppressive therapy were also determined. RESULTS: The frequency of the HLA-DR4 phenotype was significantly higher in AIH than in control subjects (59.7 % vs. 41.8 %, P < 0.001), and the relative risk was 2.14 (95 % CI; 1.51–3.04). HLA-DR4–positive AIH patients were younger than HLA-DR4–negative patients (P = 0.034). Serum IgG and IgM levels were higher (P < 0.001 and P = 0.007, respectively) in HLA-DR4–positive patients. These differences were more prominent in elderly AIH patients. However, there was no difference in IgG and IgM levels between HLA-DR4–positive and HLA-DR4–negative patients of the young-to-middle-aged group. There were no differences in the histological features. In patients with refractory to immunosuppressive therapy, higher total bilirubin, longer prothrombin time, lower serum albumin, and lower platelet count were found. Imaging revealed splenomegaly to be more frequent in refractory patients than in non-refractory patients (60.0 % vs. 30.8 %, P = 0.038). HLA-DR phenotype distribution was similar regardless of response to immunosuppressive therapy. CONCLUSIONS: HLA-DR4 was the only DR antigen significantly associated with Japanese AIH. The clinical features of HLA-DR4–positive AIH differed between elderly patients and young-to-middle-aged patients. Treatment response depended on the severity of liver dysfunction but not on HLA-DR antigens.
format Online
Article
Text
id pubmed-4618735
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46187352015-10-25 Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis Furumoto, Yohei Asano, Toru Sugita, Tomonori Abe, Hiroshi Chuganji, Yoshimichi Fujiki, Kazuhiko Sakata, Akihiko Aizawa, Yoshio BMC Gastroenterol Research Article BACKGROUND: The role of HLA-DR antigens in the clinicopathological features of autoimmune hepatitis (AIH) is not clearly understood. We examined the implications of HLA-DR antigens in Japanese AIH, including the effect of HLA-DR4 on the age and pattern of AIH onset, clinicopathological features, and treatment efficacy. METHODS: A total of 132 AIH patients consecutively diagnosed and treated in 2000–2014 at 2 major hepatology centers of eastern Tokyo district were the subjects of this study. The frequency of HLA-DR phenotypes was compared with that in the healthy Japanese population. AIH patients were divided into HLA-DR4–positive or HLA-DR4–negative groups and further sub-classified into elderly and young-to-middle-aged groups, and differences in clinical and histological features were examined. Clinical features associated with the response to immunosuppressive therapy were also determined. RESULTS: The frequency of the HLA-DR4 phenotype was significantly higher in AIH than in control subjects (59.7 % vs. 41.8 %, P < 0.001), and the relative risk was 2.14 (95 % CI; 1.51–3.04). HLA-DR4–positive AIH patients were younger than HLA-DR4–negative patients (P = 0.034). Serum IgG and IgM levels were higher (P < 0.001 and P = 0.007, respectively) in HLA-DR4–positive patients. These differences were more prominent in elderly AIH patients. However, there was no difference in IgG and IgM levels between HLA-DR4–positive and HLA-DR4–negative patients of the young-to-middle-aged group. There were no differences in the histological features. In patients with refractory to immunosuppressive therapy, higher total bilirubin, longer prothrombin time, lower serum albumin, and lower platelet count were found. Imaging revealed splenomegaly to be more frequent in refractory patients than in non-refractory patients (60.0 % vs. 30.8 %, P = 0.038). HLA-DR phenotype distribution was similar regardless of response to immunosuppressive therapy. CONCLUSIONS: HLA-DR4 was the only DR antigen significantly associated with Japanese AIH. The clinical features of HLA-DR4–positive AIH differed between elderly patients and young-to-middle-aged patients. Treatment response depended on the severity of liver dysfunction but not on HLA-DR antigens. BioMed Central 2015-10-21 /pmc/articles/PMC4618735/ /pubmed/26489422 http://dx.doi.org/10.1186/s12876-015-0360-9 Text en © Furumoto et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Furumoto, Yohei
Asano, Toru
Sugita, Tomonori
Abe, Hiroshi
Chuganji, Yoshimichi
Fujiki, Kazuhiko
Sakata, Akihiko
Aizawa, Yoshio
Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis
title Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis
title_full Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis
title_fullStr Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis
title_full_unstemmed Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis
title_short Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis
title_sort evaluation of the role of hla-dr antigens in japanese type 1 autoimmune hepatitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618735/
https://www.ncbi.nlm.nih.gov/pubmed/26489422
http://dx.doi.org/10.1186/s12876-015-0360-9
work_keys_str_mv AT furumotoyohei evaluationoftheroleofhladrantigensinjapanesetype1autoimmunehepatitis
AT asanotoru evaluationoftheroleofhladrantigensinjapanesetype1autoimmunehepatitis
AT sugitatomonori evaluationoftheroleofhladrantigensinjapanesetype1autoimmunehepatitis
AT abehiroshi evaluationoftheroleofhladrantigensinjapanesetype1autoimmunehepatitis
AT chuganjiyoshimichi evaluationoftheroleofhladrantigensinjapanesetype1autoimmunehepatitis
AT fujikikazuhiko evaluationoftheroleofhladrantigensinjapanesetype1autoimmunehepatitis
AT sakataakihiko evaluationoftheroleofhladrantigensinjapanesetype1autoimmunehepatitis
AT aizawayoshio evaluationoftheroleofhladrantigensinjapanesetype1autoimmunehepatitis